Tokyo’s Chugai Pharmaceutical (TYO: 4519) has announced that it has submitted for approval in Japan for faricimab, an anti VEGF/anti Ang-2 bispecific antibody.
The firm is looking to market the therapy for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Chief executive Osamu Okuda said: "DME and nAMD are major causes of blindness and vision loss in adults,” adding that the number of patients is expected to increase as the world’s population ages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze